Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go
- PMID: 33803592
- PMCID: PMC8002976
- DOI: 10.3390/jpm11030216
Translational Research in the Era of Precision Medicine: Where We Are and Where We Will Go
Abstract
The advent of Precision Medicine has globally revolutionized the approach of translational research suggesting a patient-centric vision with therapeutic choices driven by the identification of specific predictive biomarkers of response to avoid ineffective therapies and reduce adverse effects. The spread of "multi-omics" analysis and the use of sensors, together with the ability to acquire clinical, behavioral, and environmental information on a large scale, will allow the digitization of the state of health or disease of each person, and the creation of a global health management system capable of generating real-time knowledge and new opportunities for prevention and therapy in the individual person (high-definition medicine). Real world data-based translational applications represent a promising alternative to the traditional evidence-based medicine (EBM) approaches that are based on the use of randomized clinical trials to test the selected hypothesis. Multi-modality data integration is necessary for example in precision oncology where an Avatar interface allows several simulations in order to define the best therapeutic scheme for each cancer patient.
Keywords: Precision Medicine; high-definition medicine; omics; personalized medicine.
Conflict of interest statement
A.P. worked at AstraZeneca medical affair division from March 2015 to December 2018 and received personal fee from GSK and AstraZeneca. The other authors declare no conflicts of interest.
Figures
References
-
- Koga T., Chaim I.A., Benitez J.A., Markmiller S., Parisian A.D., Hevner R.F., Turner K.M., Hessenauer F.M., D’Antonio M., Nguyen N.D., et al. Longitudinal Assessment of Tumor Development Using Cancer Avatars Derived from Genetically Engineered Pluripotent Stem Cells. Nat. Commun. 2020;11:550. doi: 10.1038/s41467-020-14312-1. - DOI - PMC - PubMed
-
- Kijewska M., Viski C., Turrell F., Fitzpatrick A., van Weverwijk A., Gao Q., Iravani M., Isacke C.M. Using an In-Vivo Syngeneic Spontaneous Metastasis Model Identifies ID2 as a Promoter of Breast Cancer Colonisation in the Brain. Breast Cancer Res. 2019;21:4. doi: 10.1186/s13058-018-1093-9. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources